Trials / Completed
CompletedNCT00280540
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-dose Valsartan Monotherapy (80 mg) in Managing Patients With Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 648 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg compared to a more conventional approach (therapy initiated with low-dose valsartan 80 mg).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valsartan/Hydrochlorothiazide |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2006-08-01
- First posted
- 2006-01-23
- Last updated
- 2010-11-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00280540. Inclusion in this directory is not an endorsement.